NEUROLOGY 1998;51:982-985
© 1998 American Academy of Neurology
Direct genetic evidence for involvement of tau in progressive supranuclear palsy
P. Bennett, PhD,
V. Bonifati, MD,
U. Bonuccelli, MD,
C. Colosimo, MD,
M. De Mari, MD,
G. Fabbrini, MD,
R. Marconi, MD,
G. Meco, MD,
D. J. Nicholl, MRCP,
F. Stocchi, MD,
N. Vanacore, MD,
P. Vieregge, MD,
A. C. Williams, MD and
European Study Group on Atypical Parkinsonism Consortium*
From the University Department of Clinical Neurology (Drs. Bennett, Nicholl, and Williams), Queen Elizabeth Hospital, Birmingham, UK; the Department of Neurosciences (Drs. Bonifati, Colosimo, Fabbrini, Meco, Stocchi, and Vanacore), "La Sapienza" University, Rome, Italy; the Institute of Neurology (Dr. Bonuccelli), University of Pisa, Italy; the Institute of Neurology (Dr. De Mari), University of Bari, Italy; the Neurology Section (Dr. Marconi), "Misericordia" Hospital, Grosseto, Italy; and the Department of Neurology (Dr. Vieregge), Medical University of Lubeck, Germany.
Address correspondence and reprint requests to Dr. Phil Bennett, University of Birmingham, Department of Psychiatry, Queen Elizabeth Psychiatric Hospital, Mindelsohn Way, Edgbaston, Birmingham, B15 2QZ UK.
Objective: To confirm whether a dinucleotide repeat sequence in an intron of the microtubule-associated protein tau is associated with progressive supranuclear palsy (PSP) in an independent study population and to establish an improved methodology for allelotyping.
Background: It has recently been reported that a genetic variant of tau, known as the A0 allele, was represented excessively in PSP patients when compared with control subjects.
Methods: In a multicenter study, the authors examined the allelic distribution of this dinucleotide repeat marker in a set of clinically ascertained PSP patients (n = 30), multiple system atrophy (MSA) patients (n = 35), and matched control subjects (n = 70). Individuals were allelotyped using automated analysis of fluorescently labeled PCR products.
Results: The A0 allele was significantly overrepresented in the PSP patients (93.3% versus 76.4%; p = 0.0067; odds ratio [OR] = 4.33; 95% confidence interval [CI], 1.36 to 13.60), but not in the MSA patients. Likewise, A0 homozygotes were overrepresented in the PSP group (86.7% versus 61.1%; p = 0.02; OR = 4.14; 95% CI, 1.19 to 14.48) compared with control subjects.
Conclusions: The findings of this study, which is the largest to date, support those of a previous investigation that used pathologically confirmed PSP patients. These data provide additional strong evidence that genetic variation at or near the tau gene plays an important role in the pathogenesis of PSP.
*See the Appendix on page 985 for a listing of additional members of the ESGAP Consortium.
Supported by the Italian Ministry for University, Scientific and Technological Research grants to G.M.
Received February 18, 1998. Accepted in final form June 27, 1998.
This article has been cited by other articles:
|
|
|
|
 
A. M. Pittman, H.-C. Fung, and R. de Silva
Untangling the tau gene association with neurodegenerative disorders
Hum. Mol. Genet.,
October 15, 2006;
15(suppl_2):
R188 - R195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Simon, M. Lin, and A Pascual-Leone
"Nature versus nurture" and incompletely penetrant mutations
J. Neurol. Neurosurg. Psychiatry,
June 1, 2002;
72(6):
686 - 689.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Verpillat, A. Camuzat, D. Hannequin, C. Thomas-Anterion, M. Puel, S. Belliard, B. Dubois, M. Didic, B.-F. Michel, L. Lacomblez, et al.
Association Between the Extended tau Haplotype and Frontotemporal Dementia
Arch Neurol,
June 1, 2002;
59(6):
935 - 939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. R. Morris, G. Gibb, R. Katzenschlager, N. W. Wood, D. P. Hanger, C. Strand, T. Lashley, S. E. Daniel, A. J. Lees, B. H. Anderton, et al.
Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy
Brain,
May 1, 2002;
125(5):
969 - 975.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H R Morris, R Katzenschlager, J C Janssen, J M Brown, M Ozansoy, N Quinn, T Revesz, M N Rossor, S E Daniel, N W Wood, et al.
Sequence analysis of tau in familial and sporadic progressive supranuclear palsy
J. Neurol. Neurosurg. Psychiatry,
March 1, 2002;
72(3):
388 - 390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Borghi, L. Giliberto, A. Assini, A. Delacourte, G. Perry, M. A. Smith, P. Strocchi, D. Zaccheo, and M. Tabaton
Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy
Neurology,
February 26, 2002;
58(4):
589 - 592.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Tawana and D B Ramsden
Progressive supranuclear palsy
Mol. Pathol.,
December 1, 2001;
54(6):
427 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. K. Wszolek, Y. Tsuboi, R. J. Uitti, L. Reed, M. L. Hutton, D. W. Dickson, P. M. Stanford, G. M. Halliday, W. S. Brooks, J. B.J. Kwok, et al.
Progressive supranuclear palsy as a disease phenotype caused by the S305S tau gene mutation
Brain,
August 1, 2001;
124(8):
1666 - 1670.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Houlden, M. Baker, H.R. Morris, N. MacDonald, S. Pickering-Brown, J. Adamson, A.J. Lees, M.N. Rossor, N.P. Quinn, A. Kertesz, et al.
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype
Neurology,
June 26, 2001;
56(12):
1702 - 1706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. B. Baker and E. B. Montgomery Jr.
Performance on the PD test battery by relatives of patients with progressive supranuclear palsy
Neurology,
January 9, 2001;
56(1):
25 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Higgins, L. I. Golbe, A. D. Biase, J. Jankovic, S. A. Factor, and R. L. Adler
An extended 5'-tau susceptibility haplotype in progressive supranuclear palsy
Neurology,
November 14, 2000;
55(9):
1364 - 1367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Stanford, G. M. Halliday, W. S. Brooks, J. B. J. Kwok, C. E. Storey, H. Creasey, J. G. L. Morris, M. J. Fulham, and P. R. Schofield
Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: Expansion of the disease phenotype caused by tau gene mutations
Brain,
May 1, 2000;
123(5):
880 - 893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Vanacore, V. Bonifati, G. Fabbrini, C. Colosimo, R. Marconi, D. Nicholl, U. Bonuccelli, F. Stocchi, P. Lamberti, G. Volpe, et al.
Smoking habits in multiple system atrophy and progressive supranuclear palsy
Neurology,
January 11, 2000;
54(1):
114 - 114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Nicholl, P. Bennett, L. Hiller, V. Bonifati, N. Vanacore, G. Fabbrini, R. Marconi, C. Colosimo, P. Lamberti, F. Stocchi, et al.
A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders
Neurology,
October 22, 1999;
53(7):
1415 - 1415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Higgins, R. L. Adler, and J. M. Loveless
Mutational analysis of the tau gene in progressive supranuclear palsy
Neurology,
October 22, 1999;
53(7):
1421 - 1421.
[Abstract]
[Full Text]
|
|
|
|
